MA31159B1 - Composés [1,2,3]benzotriazinone substitués en position 3 destinés à améliorer les réponses synaptiques glutamatergiques - Google Patents

Composés [1,2,3]benzotriazinone substitués en position 3 destinés à améliorer les réponses synaptiques glutamatergiques

Info

Publication number
MA31159B1
MA31159B1 MA32133A MA32133A MA31159B1 MA 31159 B1 MA31159 B1 MA 31159B1 MA 32133 A MA32133 A MA 32133A MA 32133 A MA32133 A MA 32133A MA 31159 B1 MA31159 B1 MA 31159B1
Authority
MA
Morocco
Prior art keywords
glutamerge
benzotriazinone
qualifies
answers
posture
Prior art date
Application number
MA32133A
Other languages
Arabic (ar)
English (en)
Inventor
Rudolf Mueller
Stephen Lee
Sean O'hare
Gary Rogers
Stan Rachwal
Leslie STREET
Original Assignee
Cortex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortex Pharma Inc filed Critical Cortex Pharma Inc
Publication of MA31159B1 publication Critical patent/MA31159B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pest Control & Pesticides (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne la prévention et le traitement de l'insuffisance cérébrale, y compris l'amélioration du fonctionnement des récepteurs dans les synapses dans les réseaux cérébraux responsables de comportements d'ordre plus élevé. Ces réseaux cérébraux sont impliqués dans les capacités cognitives liées à l'affaiblissement de la mémoire, comme il est observé dans une variété de démences et dans des déséquilibres de l'activité neuronale entre différentes régions du cerveau, comme il est suggéré dans des troubles tels que la maladie de parkinson, la schizophrénie et des troubles affectifs. Dans un aspect particulier, la présente invention concerne des composés utiles dans le traitement de telles conditions, et des procédés d'utilisation de ces composés pour un tel traitement.
MA32133A 2007-01-03 2009-07-31 Composés [1,2,3]benzotriazinone substitués en position 3 destinés à améliorer les réponses synaptiques glutamatergiques MA31159B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87862607P 2007-01-03 2007-01-03
PCT/US2007/026415 WO2008085505A1 (fr) 2007-01-03 2007-12-28 Composés [1,2,3]benzotriazinone substitués en position 3 destinés à améliorer les réponses synaptiques glutamatergiques

Publications (1)

Publication Number Publication Date
MA31159B1 true MA31159B1 (fr) 2010-02-01

Family

ID=39608955

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32133A MA31159B1 (fr) 2007-01-03 2009-07-31 Composés [1,2,3]benzotriazinone substitués en position 3 destinés à améliorer les réponses synaptiques glutamatergiques

Country Status (21)

Country Link
US (1) US20100041647A1 (fr)
EP (1) EP2114158B1 (fr)
JP (1) JP2010514837A (fr)
KR (1) KR20090098999A (fr)
CN (1) CN101626686A (fr)
AP (1) AP2009004915A0 (fr)
AR (1) AR064739A1 (fr)
AU (1) AU2007342364A1 (fr)
BR (1) BRPI0720323A2 (fr)
CA (1) CA2674321A1 (fr)
CO (1) CO6210740A2 (fr)
CR (1) CR10913A (fr)
EA (1) EA200900937A1 (fr)
EC (1) ECSP099538A (fr)
IL (1) IL199662A0 (fr)
MA (1) MA31159B1 (fr)
MX (1) MX2009007209A (fr)
NZ (1) NZ578290A (fr)
TN (1) TN2009000278A1 (fr)
WO (1) WO2008085505A1 (fr)
ZA (1) ZA200905065B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2144506T3 (pl) * 2007-01-03 2012-04-30 Servier Lab 3-podstawiony-[1,2,3]-benzotriazynon jako związek do wzmacniania odpowiedzi glutaminianergicznych
KR101599661B1 (ko) * 2007-05-17 2016-03-03 코텍스 파마슈티칼스, 인크. 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 이치환된 아미드 화합물
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
BRPI0823262A2 (pt) * 2007-08-10 2013-09-24 Cortex Pharma Inc mÉtodo de tratamento de depressço respiratària e uso de um composto na fabricaÇço de um medicamento para o tratamento de depressço respiratària
KR20100063087A (ko) * 2007-09-20 2010-06-10 코텍스 파마슈티칼스, 인크. 글루타메이트 시냅스 반응 향상을 위한 3-치환된 1,2,3-트리아진-4-온 및 3-치환된 1,3-피리미디논
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
EP3485882A1 (fr) 2013-01-25 2019-05-22 Case Western Reserve University Compositions pour le traitement de troubles envahissants du développement
CN105418525B (zh) * 2015-12-16 2017-12-15 郑州轻工业学院 一种n‑取代1,2,3‑苯并三嗪‑4‑酮的制备方法
CN114716416B (zh) * 2022-04-11 2023-06-16 湖北大学 3,4-二氢吡咯衍生物及其一锅法合成

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723436A (en) * 1971-02-25 1973-03-27 Sun Oil Co Process for aromatic lactams
FR2597103B1 (fr) * 1986-04-15 1988-12-16 Provesan Sa Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde
GB9202915D0 (en) * 1992-02-12 1992-03-25 Wellcome Found Chemical compounds
NZ255097A (en) * 1992-07-24 2001-04-27 Univ California Heterocyclic derivatives (such as 1-(1,4-bgenzodioxan-5-ylcarbonyl)-1,2,3,6-tetrahydropyridine) and medicaments that enhance synaptic responses
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US6030968A (en) * 1996-09-17 2000-02-29 The Regents Of The University Of California Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
US6713474B2 (en) * 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6303542B1 (en) * 2000-08-18 2001-10-16 Rohm And Haas Company Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones
MXPA04004815A (es) * 2001-11-26 2005-02-17 Cortex Pharma Inc Compuestos de carbonilbenzoxazina para mejorar respuestas sinapticas, glutamatergicas.
AUPS255202A0 (en) * 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
DE10238865A1 (de) * 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB0317482D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
PL2144506T3 (pl) * 2007-01-03 2012-04-30 Servier Lab 3-podstawiony-[1,2,3]-benzotriazynon jako związek do wzmacniania odpowiedzi glutaminianergicznych
KR101599661B1 (ko) * 2007-05-17 2016-03-03 코텍스 파마슈티칼스, 인크. 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 이치환된 아미드 화합물
KR20100063087A (ko) * 2007-09-20 2010-06-10 코텍스 파마슈티칼스, 인크. 글루타메이트 시냅스 반응 향상을 위한 3-치환된 1,2,3-트리아진-4-온 및 3-치환된 1,3-피리미디논

Also Published As

Publication number Publication date
ECSP099538A (es) 2009-12-28
JP2010514837A (ja) 2010-05-06
IL199662A0 (en) 2010-04-15
EP2114158A1 (fr) 2009-11-11
AU2007342364A1 (en) 2008-07-17
CO6210740A2 (es) 2010-10-20
CR10913A (es) 2009-09-21
NZ578290A (en) 2012-03-30
TN2009000278A1 (en) 2010-10-18
MX2009007209A (es) 2009-10-12
ZA200905065B (en) 2010-04-28
EA200900937A1 (ru) 2009-12-30
US20100041647A1 (en) 2010-02-18
KR20090098999A (ko) 2009-09-18
EP2114158B1 (fr) 2012-08-08
AR064739A1 (es) 2009-04-22
CN101626686A (zh) 2010-01-13
BRPI0720323A2 (pt) 2016-08-09
CA2674321A1 (fr) 2008-07-17
EP2114158A4 (fr) 2010-05-05
WO2008085505A1 (fr) 2008-07-17
AP2009004915A0 (en) 2009-08-31

Similar Documents

Publication Publication Date Title
MA31159B1 (fr) Composés [1,2,3]benzotriazinone substitués en position 3 destinés à améliorer les réponses synaptiques glutamatergiques
MA31160B1 (fr) Composé 3-substitue-[1,2,3]benzotriazinone pour améliorer les réponses synaptiques glutamatergiques.
TN2014000424A1 (fr) Agents pour le traitement de troubles impliquant la modulation des recepteurs de la ryanodine
Pierson et al. GRIN2A mutation and early‐onset epileptic encephalopathy: personalized therapy with memantine
Beste et al. Response inhibition in Huntington's disease—a study using ERPs and sLORETA
NO20064726L (no) Imidazolforbindelser for behandling av neurodegenerative forstyrrelser
MA30632B1 (fr) Anticorps humanisé
MX2011002705A (es) Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso.
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA27997A1 (fr) Composes et compositions inhibiteurs de l'activite du recepteur tyrosine kinase
MA33659B1 (fr) Dihydrobenzocycloalkyl-oxyméthyl-oxazolopyrimidinones substituées, préparation et utilisation de celles-ci
WO2008050341A3 (fr) Agents psychotropes innovants présentant une activité du glutamate sur les récepteurs nmda
MA32374B1 (fr) Composes comprenant un groupe cyclobutoxy
MA30090B1 (fr) Utilisation d'un antagoniste de CB1 pour le traitement des effets secondaires et des symptômes négatifs de la schizophrénie
MA30037B1 (fr) Compositions et procedes destines au traitement des troubles du snc
JP2009537568A5 (fr)
NO20092198L (no) Nye Triazindionderivater som GABA-B-reseptormodulatorer
WO2003045315A3 (fr) Composes carbonylbenzoxaziniques ameliorant les reponses synaptiques glutamatergiques
NO20081845L (no) Imidazolforbindelser for behandling av neurologiske lidelser
MA30661B1 (fr) Derives de n-phenyl-prenylamine pour le traitement de maladies ou troubles cognitifs, neurodegeneratifs ou neuronaux.
UA93306C2 (ru) Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций
Rostami et al. Cross-talks between the kidneys and the central nervous system in multiple sclerosis
Maruta et al. Peculiarities of comorbid addictions in neurotic disorders
Abaroa et al. Myoclonus and angiokeratomas in adult galactosialidosis
Alekseevic The characteristics of cognitive functioning, negative and affective symptoms in the structure of schizophrenia spectrum disorders